Alligator Bioscience AB Sustainability Reports
Alligator Bioscience AB is a clinical-stage biotechnology company that develops tumor-directed immunotherapies for cancer treatment. The company primarily focuses on designing bispecific antibodies and targeting the CD40 pathway to stimulate the immune system against metastatic pancreatic cancer and other oncology indications.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300E15VI0MB7LXV19
FIGI: BBG001T92101
11 reports from 2016 to 2025
